Pegbio Co-h Stock price
Is Pegbio Co-h a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Pegbio Co-h Stock Analysis
Analyst Opinions
9 Analysts have issued a Pegbio Co-h forecast:
Analyst Opinions
9 Analysts have issued a Pegbio Co-h forecast:
Don't miss a Thing! We will send you all news about Pegbio Co-h directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
PegBio Co., Ltd. is a biotechnology company, which engages in the research, development and production of innovative drugs in the field of chronic disease treatment. The firm's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The firm's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The firm's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).
| Head office | China |
| Employees | 58 |
| Website | www.pegbio.com |


